Benjamin Kornitzer - 14 Feb 2023 Form 4 Insider Report for agilon health, inc. (AGL)

Role
Chief Med. & Quality Officer
Signature
/s/ Timothy Bensley, as Attorney-in-Fact
Issuer symbol
AGL
Transactions as of
14 Feb 2023
Net transactions value
-$475,470
Form type
4
Filing time
16 Feb 2023, 16:37:53 UTC
Previous filing
03 Feb 2023
Next filing
09 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGL Common Stock Options Exercise $232,670 +25,881 +248% $8.99 36,307 14 Feb 2023 Direct F1
transaction AGL Common Stock Sale $594,877 -25,881 -71% $22.99 10,426 14 Feb 2023 Direct F1, F2, F3
transaction AGL Common Stock Options Exercise $72,765 +8,094 +78% $8.99 18,520 15 Feb 2023 Direct F1
transaction AGL Common Stock Sale $186,028 -8,094 -44% $22.98 10,426 15 Feb 2023 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGL Options (Rights to Buy) Options Exercise $0 -25,881 -14% $0.000000 165,470 14 Feb 2023 Common Stock 25,881 $8.99 Direct F5
transaction AGL Options (Rights to Buy) Options Exercise $0 -8,094 -4.9% $0.000000 157,376 15 Feb 2023 Common Stock 8,094 $8.99 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes restricted stock units.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.66 to $23.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.89 to $23.125, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 These options were granted on January 31, 2020 and vested on September 14, 2021.